Inge K.
- Country
- The Netherlands
- Department
- Medical Oncology
Research Overview
- Palazestrant and Ribociclib versus Letrozole and Ribociclib for First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy
- Evaluation of CDK4/6 Inhibitors Abemaciclib, Palbociclib, and Ribociclib in HR+/HER2- Metastatic Breast Cancer: A Randomized Clinical Trial
Data & Insights
Has run more than one trial at 74 of 231 partner sites.
Specializations
Breast Cancer Research
This investigator specializes in the treatment of HER2-positive breast cancer, with particular emphasis on high-risk cases requiring targeted therapeutic approaches.
- Advanced Treatment Modalities
- Post-Neoadjuvant Therapy
- Residual Disease Management
The investigator's work focuses on evaluating innovative therapeutic strategies for breast cancer patients who have undergone initial treatment.
Targeted Therapies
Research interests center on antibody-drug conjugates in oncology, specifically exploring comparative effectiveness of different therapeutic agents for breast cancer treatment.
- HER2-Targeted Treatments
- Novel Therapeutic Approaches
- Comparative Treatment Studies
The investigator evaluates advanced therapeutic options for patients with specific molecular subtypes of breast cancer.
Clinical Outcomes
Specialized focus on invasive disease-free survival outcomes in breast cancer patients, particularly examining therapeutic effectiveness in high-risk populations.
- Treatment Response Assessment
- Risk Stratification
- Long-term Outcome Analysis
The research encompasses evaluation of treatment efficacy in patients with residual disease following initial therapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.